The United States is deeply unsettled by the prospect of losing its global hegemonic status to China, a shift that challenges its national identity. Since the Second World War, America has been positioned as the world’s economic, technological and military leader, a role intertwined with its sense of exceptionalism. China’s rapid ascent, backed by state-led industrial strategy, expanding global influence, and technological ambition, poses a direct threat to U.S. supremacy.
Countries with current account deficits should find it easier to strike deals with the Trump administration because they have more flexibility in reaching a balanced trade position with the USA, i.e. they can buy stuff from the United States to appease politicians. Trump has repeatedly framed global trade as a zero-sum game, where US deficits equate to losses, and surpluses indicate exploitation. This is how Liberation Day was framed where countries with bilateral deficits with the USA had the minimum 10% tariffs and trade surplus countries had much higher tariffs. In this context, countries that run deficits are less threatening and more likely to be dependable trading partners. Moreover, deficit countries often share concerns about global imbalances and may be more amenable to bilateral arrangements that emphasize domestic industry protection, supply chain re-shoring, and nationalist economic policies. The initial information we have on the trade deal between the United Kingdom and the United States is an example where the UK has essentially given a veto to the US to reject Chinese company purchases. The table below highlights some of the countries that run current account deficits. The first deal announced is with the UK. Discussions with India seem to be advancing. The case of Japan is slightly more complicated because its current deficit account status is highly dependent on the price of commodities since they import most of them. With lower commodity prices, a current account deficit will rapidly swing to a surplus. Initial indications are that Japan will be among the early deals. We added Canada to the list, even if it currently runs a surplus, since Canada, Mexico and the USA will probably modify their current trade deal (USMCA). Canada is the opposite of Japan where low commodity prices can swiftly shift it to a current account deficit country.
Countries with large current account surpluses—such as those in the graph below, are likely to face tougher trade negotiations with the United States because they are seen as benefitting disproportionately from global trade. A surplus implies these countries export significantly more than they import, often into large consumer markets like the U.S. The White House argues that imbalances reflect unfair advantages such as undervalued currencies, protectionist policies, or state support for export-driven sectors. The U.S. will demand concessions like greater market access, reduced subsidies, or currency adjustments and tariff rates greater than the minimum 10% are likely to stay for the countries that run current account surpluses. China and re-routing countries such as Indonesia, Vietnam and Malaysia are the main targets. The European Union may also encounter more difficult negotiations than currently expected, even if it is a historical ally.
It is clear that pursuing maximum cost efficiency is no longer the main goal of our evolving economic system; the prospects for globalization are dimming. GDP for consumption sake will get replaced by industrial policy where resiliency is more important and how money is spent counts. For example, investments in the US shipbuilding industry are more important than purchases of dolls even if each dollar spent results in the same when measuring economic output.
Biden used carrots to re-industrialize with the Inflation Reduction Act, the Chips Act and the Infrastructure Bill. Trump is using sticks with tariffs and other coercive measures. Earlier this week, China and the United States announced a 90-day truce period to negotiate a comprehensive trade agreement. During the press conference, Scott Bessent, the US Treasury Secretary, confirmed that the United States is seeking strategic decoupling from China. This helped to reduce the temperature of the trade war, but the direction of travel is clear to both sides. Companies have been warned: do not invest in China, bring your supply chain closer to the consumer and create jobs.
When production is closer to major markets, companies can iterate products faster, ensure better quality control, and maintain greater control over labor and environmental standards. While shorter supply chains may raise production costs, it can reduce exposure to supply risks in a transforming World Order. This change signals a broader move away from a purely globalized efficiency model toward one rooted in strategic autonomy and resilience.
In the context of strategic decoupling, we identified 20 sustainable companies from our investment universe, across sectors and investment themes, that are best positioned to thrive in a deglobalizing world, specifically related to the eventual strategic decoupling of the United States from China.
The table below highlights the 20 companies, their sector, what they do and why they are not affected by the trade conflict.
Next, we examined historical performance over the last 10 years to align with the long perspective of this note. The chart below shows a list of strong performers over the last 10 years in health care (Intuitive Surgical, Vertex and Quest), utilities (Constellation) and energy (Cameco). As we can see, our selection of health care companies have done very well and they remain well-positioned for the upcoming mayhem. Cameco and Constellation Energy are both beneficiaries of the nuclear renaissance.
The following chart shows companies in the same sectors that have some catch up to do. Ormat is a geothermal utility which has not yet benefitted from the same excitement as nuclear but it could come soon since the Trump administration supports geothermal. LKQ is an auto parts recycler and Americold is a cold storage real investment trust which have not been top of mind. Vital Farms is a pasture-raised egg producer that has not yet completely recovered from the pandemic.
The next chart looks at strong performers in technology, industrials and materials. Fortinet and ServiceNow, and even Parker Hannifin benefitted from the strong performance of technology-related companies. Republic Services and Waste Management rode the wave of increased demand and consolidation in waste and recycling.
And finally in the chart below, we look at companies that have lagged in industrials and materials over the last decade. Most of the companies on the chart below were performing very well until recently when the risk of recession increased and engulfed Commercial Metals, First Solar, Freeport, ArcBest and even Packaging Corporation. We believe those companies will benefit from strategic decoupling that will favor local producers and shorter supply chains. Their recent drops in price reflects the risk of a recession emanating from less global commerce. In our view, these companies could reverse higher once/if a recession gets fully reflected in their price.
As we have highlighted in past notes, the world’s population is getting older and this is especially the case in developed countries. Across Europe and North America, the share of persons aged 65 and older will reach 25% by 2040.
These demographic changes create structural demand for senior living facilities. The Baby Boomer generation is living longer, spending more years as a senior, spurring demand for both independent and assisted living as well as residences offering higher levels of care. Furthermore, in the United States, the supply of senior housing is not keeping pace with demand.
In addition to growing demand, senior living facilities’ largely domestic operations make them less vulnerable to tariffs and global supply chain challenges. Obviously, this industry is not without its challenges. Risks include labor shortages whereby stricter immigration policy could affect the high share of foreign-born nursing assistants, and the potential for significant cuts to Medicare depending on how the House-approved budget framework progresses into a formal bill.
Still, amidst the current economic backdrop of stagflation and heightened recession risk, we find this sector attractive. We favor REITs in particular; in addition to less cyclical demand, they are relatively insulated from rising operational costs, which are mainly borne by their tenants, and benefit from stable rental income and inflation pass-through in their lease agreements. Many eldercare REITs also offer attractive dividend yields. Furthermore, within the REITs segment, investors can choose from different business models with distinct risk-return profiles. Given their appeal in the current context, we focus on REITs for the remainder of the note.
The REIT Stuff: A Senior Housing Breakdown
Senior care REITs own and manage assets such as independent living facilities, assisted living facilities and skilled nursing facilities. To screen for these companies, we identified REITs earning at least 65% of revenues from senior housing and with a market capitalization over USD 1 billion. We then excluded companies with a score below 55% in our proprietary ESG-Materiality Score, which assesses factors material to these companies’ impact—namely product responsibility, energy & climate change, and resource management. We also screened for controversies; one might recall the Orpea scandal in France, which highlighted severe governance and human rights failures in senior care. To account for such risks, we excluded companies with either ongoing severe controversies or structural weaknesses in managing ESG risks—such as inadequate responses to past controversies or weak governance and oversight mechanisms. The five resultant companies are presented in the table below.
Within the senior care REIT space, two distinct business models offer different risk-return profiles for investors.
- Triple-Net Lease
Commonly used for skilled nursing facilities, this structure minimizes exposure to operational costs. The REIT leases the facility for a fixed rent and the operator assumes full responsibility for the three main expenses: taxes, maintenance and insurance in addition to the operational costs. This model provides predictable, stable income and insulation from rising operating costs, but limits exposure to revenue growth.
- Senior Housing Operating Portfolio (SHOP)
In contrast, the SHOP model enables the REIT to share in revenue growth by partnering with operators who manage the facilities. In addition to rental income, the REIT is exposed to revenue from resident fees, services and amenities but the landlord also pays more of the property expenses. This offers more upside potential, but also greater volatility.
Though we expect senior care to benefit from strong, non-cyclical demand growth, the ability to choose between these two models – more growth-oriented SHOP or stable-income triple-net – gives investors flexibility in tailoring their exposure based on risk appetite and market outlook.
Three of the companies we identified operate with the triple-net lease model: Omega Healthcare Investors, Cofinimmo and Aedifica. The remaining two, Welltower and Ventas, are mixed between triple-net lease and SHOP, but with greater emphasis on the SHOP model. Given this combined approach we refer to Welltower and Ventas as having a “mixed” strategy for the remainder of the note.
Elder Economics: Performance Drivers for Senior Care REITs
Acquisition strategies play a key role in driving growth for these REITs regardless of their lease structure. Buying properties enables portfolio expansion and diversification across geographic regions and care models. The table below highlights major property acquisitions by Welltower, Ventas and Omega over the past five years.
Welltower, Ventas, and Omega are among the most active acquirers in American healthcare REITs over the past five years. Each has acquired more properties than their peers’ average and for Welltower and Ventas, at higher total transaction values.
For the two European REITs, Cofinimmo and Aedifica, comparable standardized data on acquisitions was not available. However, both appear to have focused less on acquisitions in recent years compared to their American counterparts. Their 2024 annual reports point to a strategic pivot toward upgrading, developing, and maintaining existing senior care facilities, alongside divestments in non-core segments: Aedifica is exiting its portfolio of school buildings in Sweden, while Cofinimmo has accelerated its shift from offices to healthcare, having sold €700 million worth of office assets over the past three years.
Over the past two years, the performance of the highlighted healthcare REITs has diverged significantly, shaped by differences in national markets and strategic activities.
Mixed strategies have outperformed in the past two years. Welltower and Ventas have benefited from rising occupancy and pricing power in senior housing amid strong demand and limited new supply. They acquired assets below replacement cost (purchasing a property for less than what it would cost to build the same asset today) and put strong emphasis on their SHOP segment. Welltower enhanced revenue by converting many triple-net leased properties into SHOP structures, and Venta’s SHOP segment is expected to generate over half of Ventas’s total revenue in 2025.
Among the three triple-net lease companies, Omega Healthcare has significantly outperformed its peers. Aside from higher acquisition activity, a key differentiator versus the European triple-net lease companies is Omega’s exposure to Skilled Nursing Facilities (SNFs), which represent 64% of its portfolio. As the largest U.S. owner of SNFs, Omega benefits from the higher yields typically associated with this asset type. Among the different types of senior care, SNFs have the least elastic demand compared to independent or assisted living facilities but these tenants also have greater operational risks, such as labor and rising costs, due to the higher level of care required. The risk of these tenants is reflected in Omega’s higher cap rate of 6.5% – notably higher than the 3.0% and 4.0% for Welltower and Ventas, respectively. This cap rate serves as a proxy for investment risk. Furthermore, while many seniors depend on Medicare and Medicaid, Omega has 81% of its payor mix from these programs, making it particularly sensitive to any changes.
European peers, Aedifica and Cofinimmo, are subject to greater regulatory constraints, particularly in Belgium and Germany, where rent indexation and pricing flexibility are limited by the structure of public senior care funding. This, coupled with weaker acquisition activity could explain their recent underperformance; however, both companies have delivered strong revenue growth over multiple years and remain well positioned to benefit from long-term demand drivers such as population ageing and the need to modernize care infrastructure. Because of this and their more attractive valuations (see below), we favor them over the riskier Omega in the triple-net lease category. On this basis we eliminate Omega from the rest of our analysis.
Financial Health of Selected REITs
Following our strategic assessment, we now examine the financial fundamentals of the four REITs best positioned for long-term upside.
Here are the main takeaways from this table:
- Growth: Despite greater acquisition activities by their peers, Aedifica has the highest CAGR over a three-year period at 18.9%, followed by Cofinimmo at 10.3%. While the U.S. REITs show stronger short-term momentum, the European triple-net names have delivered steadier long-term growth. Note, Cofinimmo’s dip in revenues in 2024 reflects a strategic repositioning rather than core business weakness, as it scaled back office assets to focus on its healthcare activities.
- Cash-Flow & Profitability: U.S. REITs report Core Funds From Operations (Core FFO), a metric that adjusts net income to better reflect recurring operational performance, used to assess underlying profitability. European peers report EPRA Earnings, a standardized measure that focuses on rental income and excludes fair value changes and one-time items. NOI, or Net Operating Income, captures property-level income before financing and taxes. Welltower posted the strongest growth in both Core FFO and NOI, reflecting strong momentum. In contrast, Ventas showed more modest gains. The triple-net lease REITs reported moderate Core FFO growth and slower NOI expansion—consistent with their model of predictable, inflation-linked lease revenues.
- Valuation: On a Price-to-FFO basis — the REIT equivalent of P/E — Welltower commands a premium multiple, while Ventas, Aedifica, and Cofinimmo are cheaper. The pattern repeats on a NAV basis: Welltower trades at a 79% premium, while Aedifica and Cofinimmo trade at discounts, suggesting potential undervaluation or lower growth expectations for the European names.
- Dividend yields: Higher for the European triple-net REITs, reflecting the stable, inflation-linked nature of their income streams.
- Balance Sheet: Debt metrics are strongest for Welltower, Aedifica, and Cofinimmo, all with debt ratios under 45%. Ventas appears more leveraged by comparison. Interest coverage is particularly solid among the European players. European companies have better occupancy rates (98.5–100%), while mixed-model REITs hover in the mid-80% range — leaving room for upside, but with increased operational risk.
Our top picks of healthcare REITs offer a combination of strong sustainability performance, stable income, and diversified risk-return profiles that can weather both market and policy headwinds. Within the Mixed REITs, Welltower stands out for its recent momentum— though this comes with a premium valuation. Ventas is cheaper but its lower growth and higher leverage temper the appeal. Among the triple-net lease companies, Aedifica and Cofinimmo, stand out for their deep NAV discounts, high and secure dividend yields and strong balance sheets.
The opening months of 2025 have seen market swings, volatility spikes and ripening conditions for a bear market. Politics and geopolitics have taken central stage and will drive investment outcomes for sustainability portfolios for the remainder of the year and beyond. In this installment of our quarterly update on Macro Meets Sustainability, we argue that despite the noise emanating from Washington, in terms of concrete policy action, the euro area’s recent (fiscal) policy moves are the more significant market driver. We also underscore our view, outlined in several recent notes, that global inflation risks are rising while economic growth momentum is slowing, creating a stagflationary environment. The implication is that the rotation to defensive sectors and to euro area stocks has further to go.
U.S. Noise and Euro Area Action
Contrary to mainstream media and financial pundits, our observation is that U.S. policy changes have underwhelmed so far in 2025; the biggest surprises and significant policy action have occurred in the euro area:
In the U.S., the daily headlines of federal firings, deportations, and tariff threats means the Trump’s administration occupies most of the space. However, what has actually been accomplished on any of these fronts?
In terms of DOGE, it’s difficult to know exactly how many layoffs have taken place but estimates of federal job separations in February were about 60 000, an insignificant number in an economy that employs over 160 million people. To be sure, the immeasurable loss of experience in federal institutions is lamentable and sows the seeds for challenges in the future. However, the impact on economic activity in the near term is likely to be very low.
Meanwhile, although much has been threatened, tariffs imposed on trading partners are so far only slightly more punitive than what occurred during Trump’s first term, which had little impact on overall global activity. The range of possibilities on what comes next is extremely wide, but a pattern has emerged whereby U.S. tariff barks have been worse than the bites.
Finally, while we continue to believe that over time, the level of illegal (and legal) immigration to the U.S. will be aggressively curbed, ICE is operating with the same budget that it had on Jan. 19. This suggests that it is highly unlikely that the government’s targets of over 1000 arrests per day are even close to being met; only the most migrant worker-dependent sectors like agriculture will feel the near-term impacts of current U.S. immigration policy.
In contrast, the threats and proclamations of the Trump administration have been sufficient to shake European policymakers out of their torpor as they seem to be working with renewed vigor. On Tuesday, the German parliament approved Chancellor Merz’s plan to spend up to €1 trillion in coming years on infrastructure and defense. EUR500B is earmarked for infrastructure and green initiatives. This massive spending deal means that just the infrastructure fund alone adds over 1% to GDP over the next decade, even without applying a fiscal multiplier (i.e. positive knock-on effect). Added on to this is the announcement in early March by Ursula von der Leyen that the new “ReArm Europe” investment plan will unlock a €150 billion loan scheme to help Member States invest in key military capabilities.
Our key takeaway is that while investors must stay attuned to possible impacts on global growth and financial markets stemming from the U.S., so far in 2025, realized policy activity has been more significant in Europe than in North America. This provides at least a partial foundation for why we expect the outperformance of euro area equities to continue for the next few quarters.
It’s Still The Economy, Stupid
Although it is well known that financial markets respond poorly to economic and policy uncertainty, the current instability in risk assets can not be solely attributed to uncertainty arising from Trump’s leadership style (described as “flooding the zone”). Indeed, U.S. economic growth was losing momentum well before Trump moved into the White House, and earnings expectations were also ratcheting down prior to Trump’s inauguration.
One very well-known and favored indicator is the economic surprise index, which tracks the strength of incoming data relative to expectations. In the U.S., the economic surprise index peaked in November and is now in negative territory, meaning that data is weaker than forecasted. In the euro area the indicator displays the opposite trend (data is surprising to the upside). The chart below shows the surprise indicator for the U.S.
Of course, the above analysis is only useful in that it helps explain what has already happened. However, in the U.S. there is likely to be more months of negative surprises before an inflection point is reached because economic surprise indices tend to be mean-reverting and swing in regular patterns – it takes time for expectations adjust to economic reality.
Beyond this, there are three reasons we expect that the environment for euro area stocks will support continued performance for the next few quarters:
1. More room for fiscal and monetary support outside of the U.S.: though it’s unknown to what extent Trump’s ambitions will translate into action, the direction of travel on virtually all of his stated plans translates to: more inflation and less growth in the near-term. We have written about the inflationary impulse in previous notes (for example, see “Food Fight: Policy’s Effect on Food Producers & Inflation”, February 13, 2025 and “Playing the Trump Card”, November 21, 2024) and the Fed’s updated FOMC projections yesterday are very much in line with our view. In plain language, Federal Reserve Chair Jay Powell acknowledged that further progress on inflation was likely to be “delayed for the time being”. The corollary is that the U.S. Federal Reserve may not have the leeway to loosen monetary policy given its 2% inflation target. Indeed, the OECD recently updated its inflation forecasts. With assumptions about future tariffs, the inflationary impact is strongest in North America.
As discussed above, Germany is already forging a new path for fiscal policy and we expect other countries with the fiscal space will follow suit, whether it be in the form of relief to businesses to offset the tariff shock (as announced in Canada) or to raise defense spending.
2. Euro area sustainability stocks still trade at a discount relative to their U.S. counterparts. Euro area stocks have been comparatively cheap for years, but the recent divergence in price performance has done little to correct this gap. This is also true for the Sustainable Market Strategies’ sustainability universe. The average forward P/E for euro area stocks in our universe is 18 compared to 29 for the U.S.
3. The U.S. has Mag 7, but the euro area has defense stocks. The U.S. equity outperformance streak in 2023-2024 was without a doubt characterized by a strong tailwind emanating from the Magnificent 7 stocks and a bubble for everything artificial intelligence. China’s Deepseek helped to burst the bubble earlier this year. In contrast, we believe the prime candidate for a future “bubble” sector in the euro area is still in full swing. As we wrote in a recent note, “The European Defense Offensive: From Peace Dividend to War Premium”, the European Commission has recently unveiled an ambitious plan to mobilize approximately $840 billion to bolster the EU’s collective defense capabilities. There is a clear bias for European countries to invest in European defense companies, and despite the near parabolic rise in the biggest defense names, there are still several companies with moderate valuations that satisfy our strict sustainability criteria. But even for investors that do not wish to be long defense companies, the “euphoria” surrounding this sector will likely lift related stocks, especially euro area industrials. On this basis, just as the U.S. tech sector is becoming a drag on broad U.S. equity indices, the bull market in the euro area defense sector could boost European indices.
In sum, despite the fact that geopolitical tensions are emanating from the U.S. and onto the rest of the world, we expect that euro area stocks will continue to outperform.
Defensive Rotation Is Justified
Stocks in defensive sectors like health care, consumer staples and utilities outperform when uncertainty is high and/or when recession risks are elevated because it is difficult to cut back on essential spending.
From a sustainability standpoint these sectors are often appealing because underlying products and services can create positive impact on individual lives. In recent weeks, we have written notes on two of these critical sectors – health care and food staples – and how sustainability investors should maintain a postive bias in this space despite needing to navigate the ongoing policy crosscurrents. Developments over the past few weeks only serve to strengthen our conviction. Interestingly, euro area stock markets tend to have a greater exposure to defensive sectors (healthcare is about 16% in the Eurostoxx 600 index versus 10% in the S&P 500), which also helps to explain some of the European outperformance in recent weeks.
In times of economic uncertainty, investors turn to defensive sectors like healthcare. After all, people need medical care regardless of economic conditions.
But like almost all sectors in financial markets, healthcare is not immune to the volatility emanating from the new U.S. administration. Investors seeking stability in this impactful sector must navigate Trump’s desire to shakeup the U.S. healthcare system and Make America Healthy Again. Admittedly, this is a tall order since deciphering the signal from the noise during the Trump regime is difficult. However, of the eleven executive orders addressing aspects of U.S. health care, we believe there are three key areas to focus on:
- A desire to improve drug price transparency; An executive order for clear, accurate and actionable healthcare pricing information signed on February 25th signals a potential shakeup for a system that has long thrived on opacity. Though it lacks specific details, simply tasking relevant agencies – Health and human services, Treasury and Labor – with expanding enforcement of price initiatives introduced in Trump’s first term, the order shows that price transparency remains a priority.
- A desire to reduce the breadth of government-sponsored coverage: An executive order reversing Biden era efforts to expand health coverage was signed on January 20th. It amounts to making it more difficult for citizens to access coverage. Moreover, the budget passed in the House on February 25th calls for $880 billion in savings from the committee overseeing the spending of these plans. Achieving the desired cost reductions looks virtually impossible without cutting funding.
- A desire to reduce the number of Americans suffering from chronic illnesses: An executive order on February 13th was signed to establish a new “Make America Health Again” commission. Its stated aim is to combat the “rising rates of mental health disorders, obesity, diabetes, and other chronic diseases” with emphasis on children.
In today’s Note, we consider these three political desires and how they affect the healthcare sector. We focus on drug producers, equipment makers and health insurance providers as these are the biggest categories within the healthcare sector and also the most at risk from policy changes. Investors looking to increase exposure to the health care sector should focus on companies with one or more of the following characteristics:
- At lower risk from drug pricing negotiations.
- A high percentage of production occurring domestically (to lower the risk of negative tariff implications).
- High exposure to chronic illnesses rather than communicable diseases.
A. Drug Production: Favor “Small” Pharma, Chronic Disease Specialists
The appointment of Robert F. Kennedy Jr, as well as an executive order on February 13th, Establishing the President’s Make America Healthy Again Commission, clearly suggests the direction of policy travel: addressing the rising number of Americans – especially children – affected by chronic illnesses is a desired priority. After all, 90% of the U.S.’ $4.5 trillion in annual health care expenditures are for people with chronic and mental health conditions.
Concurrently, one of the few areas of the Inflation Reduction Act that has stayed in place under the Trump administration is the Medicare Drug Price Negotiation Program. The program was established to allow the Department of Health and Human Services (HHS) to negotiate maximum fair prices for certain high expenditure drugs and biological products. There are currently 25 medications that are subject to price negotiation with another 35 that will come to the negotiating table in 2028 and 2029 (a timeline is provided below); all were chosen because they are among the prescription drugs for which Medicare spends the most.

The first ten drugs identified for price negotiation have already settled: new prices come into effect in 2026 and the stock prices of companies affected have already digested the news. The negotiated price for the other fifteen drugs will only be announced in November 2025. Seventeen companies produce these 25 drugs, with Novo Nordisk, GSK and Astellas Pharma having the highest Medicare revenue from drugs selected for price negotiation. However, the financial impact on each company will ultimately depend on the extent of the negotiated price reductions.
Unsurprisingly, the list of drugs subject to price negotiations features many of the largest pharmaceutical companies. In the table below, we highlight the top five players by market share in each of the five most common chronic illnesses. Note that while for some illnesses like cancer and Alzheimer’s disease, there is a more diversified market (the top five players account for less than half of total market share), for other diseases (arthritis, diabetes) only a handful of companies dominate accounting for over 75% of the total market shared.
Interestingly, the table shows just how big “big pharma” really is. Companies like Pfizer and Johnson and Johnson are among the top players in not just one, but often two or three chronic illness medications. Moreover, they often compete in many other (non-chronic disease) markets; 40% of Pfizer’s revenues are derived from infectious disease medications, and over 20% of Johnon & Johnson revenues are from vaccines.
One could argue that the diversified nature of big pharma’s activities means these companies are well protected from a specific risk or disruption in any one pharmaceutical line. We believe that in the current environment, the opposite is true: a government set on bringing down prices will continue to target the biggest players first.
Therefore, when seeking out defensive health care companies with exposure to chronic illness remedies, we look for:
- Companies with at least 1 billion USD market cap.
- Companies that are relatively concentrated within a specific illness/market, with at least 60% of revenues generated from one industry (e.g. oncology).
- Companies that are free from controversy.
By applying the above criteria, we find twelve companies in four chronic disease segments (cardiovascular, oncology, endocrinology, and neurology); we expect that ongoing drug price negotiations and President Trump’s push for greater transparency in pharmaceutical price setting will foster a more competitive price environment for smaller companies. These players also have potential as acquisition targets by larger pharmaceutical companies.
Looking at financials for these companies, we favor United Therapeutics (UTHR US), Ipsen (IPN PA) and Neurocrine Biosciences (NBIX US).
United Therapeutics is the only company identified in cardiovascular drugs. The company is specialized in drugs treating hypertension. It boasts strong margins, sales growth and a fair valuation. Despite record revenues in 2024, a slight miss on latest earnings report sent the stock price lower in late February – presenting a compelling entry point.
From the oncology segment, Ipsen is appealing: in addition to having over 70% of its revenue generated from cancer treatments, its remaining revenue sources also stem from non-communicable disease treatments (neurology medications, 19% and OTC drugs, 8%). The company’s relatively lower growth and margin profile suggest a potentially more stable investment than high-growth biotech plays. We like it for this and the associated low beta. Alternatively, the U.S. oncology company Exelixis, demonstrates higher sales growth and a stronger margin while maintaining a low beta, making it a more dynamic alternative within the space.
Within the neurology drugmakers, Neurocrine Biosciences has strong sales growth and profitability, at a reasonable valuation, with lower debt than some of its peers.
B. Healthcare Insurance: Avoid the Giants
The major U.S. health insurance providers, aka “Big Health”, are also at risk from policy efforts to crack down on healthcare costs. Their vertically integrated business models, encompassing Pharmacy Benefit Management Services (PBMs), patient care, drug distribution and other health care services, make them particularly vulnerable to systemic changes.
Cuts to Medicare and Medicaid could reduce revenues from government-managed plans – especially Medicaid, where low-income individuals are unlikely to convert to private plans. Moreover, price transparency reforms threaten profits in patient care, drug sales and PBMs. PBMs have been directly called out by Trump for their role in higher drug prices, he has threatened to “knock them out.” UnitedHealth, Cigna, CVS and Elevance account for virtually all (99.8%) of the PBM market according to FactSet data. While cuts to government-supported health coverage will face some resistance, broad dissatisfaction with the U.S. healthcare system means efforts to curb high prices will have bipartisan support, meaning there is greater likelihood that those initiatives pass.
There are some health service providers already offering an alternative approach. So-called “value-based” healthcare incentivizes patient outcomes over volume of tests, prioritizing quality over quantity and assessing value through the cost of treatment for the achieved health outcome. These companies have a competitive edge that puts them ahead of potential regulatory changes. Privia Health (PRVA US) is one such company. It partners with physicians, using technology and offering administrative support to improve patient experience and reduce unnecessary costs. Other value-based insurers like Alignment Healthcare and Clover (both also over US$1 billion in market cap) have had strong stock performance but have reported negative earnings in the past few years.
C. Healthcare Equipment: What Domestic Production?
Medical equipment makers face limited risks from healthcare policy changes but nonetheless remain exposed to trade tensions and geopolitical shifts: U.S. tariffs could increase costs for multinational manufacturers, creating advantages for domestic producers. Additionally, retaliation to tariffs, like China’s recent ban on Illumina’s gene sequencers, highlights the possibility of tit-for-tat trade wars in the sector.
Readers of our work know that healthcare equipment, especially those focused on an aging population, is one of our favored health care sub-sectors (for example, “Grandpa’s Gadgets: Healthcare Devices for Increased Longevity”, June 22, 2024). Normally, companies that specialize in joint replacement and orthopedic products, vision and hearing solutions as well as diagnostics and treatments for chronic illnesses are excellent outperformance candidates during bear markets and the recent correction is no exception, as shown in the chart below. Unfortunately, however, the trade backdrop now obfuscates the outlook.
The main lobby group for medical device makers, Advamed has already sought an exemption from Trump’s tariffs, saying that tariffs will devastate the industry. Indeed, about 70% of U.S. marketed medical devices are manufactured solely outside of the U.S., making the industry highly reliant on foreign production.
Whether the industry can negotiate a tariff carve-out is an open question, although there is a positive precedent. In 2018, Advamed effectively lobbied the Trump government and was able to severely limit the number of medical devices that were subjected to Trump’s China tariffs at that time.
In the table below, we provide a shortlist of medical device manufacturers that have strong tailwinds to their businesses, though long positions should only be activated if tariff carve-outs occur. Note that compared to pharmaceutical companies, equipment makers on average exhibit higher valuations and relatively lower beta. In particular, Edwards Lifesciences, Abbott Laboratories and Danaher stand out, combining high R&D investment, strong profitability, and solid sales growth with manageable debt.
Almost two years ago, we wrote what was then a controversial note about the role of defense companies in sustainable investing (see Defending the indefensible? An ESG perspective, May 11, 2023). Fast-forward to today, and this topic has become much more accepted, though still not quite mainstream.
In our previous note, we argued that a subset of the defense sector—specifically what we called the “European Defense Specialists” as opposed to the “American Defense Primes“—should be considered by sustainability-minded investors. Our thesis was based on two key factors: European defense companies demonstrate significantly stronger governance than their American counterparts, and European defense expenditures were poised for massive increases. This strategy has performed exceptionally well, with the SMS European Defense Specialists Basket dramatically outperforming both American Defense Primes and the S&P 500 since our May 2023 publication.
The End of Pax Americana
Recent geopolitical developments, including the Oval Office showdown between Zelenskyy, Trump, and Vance that led to the immediate freezing of all U.S. military support to Ukraine, only strengthen our thesis. What we're witnessing is essentially the end of the post-Cold War "peace dividend" era. For decades, European nations comfortably operated under the Pax Americana security umbrella, maintaining modest defense budgets while focusing on social spending and economic integration. This convenient arrangement—Europeans handling "soft power" (diplomatic influence, cultural appeal, economic incentives, and humanitarian aid) while America provided "hard power" (military might and security guarantees)—is now being fundamentally reconsidered.
Prior to 2022, only the UK, Poland, and France among major European powers were approaching or exceeding NATO's 2% target. Faced with the stark realization of their strategic vulnerability, European nations have been forced to step up.
The ReArm Europe Initiative
Earlier this week, the European Commission unveiled an ambitious plan to mobilize approximately $840 billion to bolster the EU's collective defense capabilities. This plan, dubbed "ReArm Europe," aims to provide European countries with the financial resources to modernize their armies, enhance their collective defense systems, and increase support for Ukraine.
The initiative includes a new fund worth more than $150 billion to support EU members' defense investments, while simultaneously relaxing the bloc's debt rules (effectively the "debt brake" to allow for higher defense spending). Additionally, the EU plans to leverage profits from sanctioned Russian assets (approximately $200 billion held in Europe) to help finance military assistance to Ukraine. While some, like President Zelenskyy, have floated the idea to seize and redirect these $200 billion towards security, France's finance minister has expressed opposition to this mechanism as these are Russian central bank assets and are protected by international banking agreements.
The Global Defense Spending Shift
The chart below illustrates the dramatic shift in the global balance of defense spending from 2011 to 2023. The United States has experienced a steady decline in its proportion of global defense spending, dropping from over 50% in 2011 to just 37.7% by 2023. Even in absolute terms (using constant 2022 USD), U.S. spending fell from nearly $1 trillion in 2010 to approximately $880 billion in 2023—a reduction of 12%.
Conversely, Europe (including the UK) has demonstrated remarkable growth, particularly in recent years. From 2011 to 2021, European defense spending as a percentage of the global total increased modestly from 17.9% to 19.8%. However, 2022-2023 showed dramatic acceleration, with Europe's share jumping to 24.4% by 2023—a clear response to the radically altered security environment following Russia's invasion of Ukraine. With the implementation of the ReArm Europe initiative, Europe's defense expenditures could represent over one-third of global defense spending within the next few years.
A More Sophisticated Screening Approach
These developments reinforce our conviction to focus on European Defense Specialists rather than American Defense Primes. We've expanded our analysis to include several additional critical factors:
- Allied Revenue Alignment: We assess the proportion of revenue derived from NATO and other allied nations, aiming to minimize exposure to companies with significant revenues from potentially misaligned or authoritarian regimes.
- Government Independence: We evaluate the percentage of each company owned by governments. Generally, we favor greater independence from government control to maximize innovation potential and governance quality.
- R&D Investment: We analyze R&D expenditure as a percentage of revenue. Modern warfare demands constant technological advancement—companies that fail to innovate today will be irrelevant tomorrow.
- Strategic Defense Orientation: We focus on companies specializing in technologies and systems designed primarily for defensive purposes—such as air defense systems, cybersecurity solutions, and intelligence platforms—rather than offensive-oriented activities like armored assault vehicles, strike missiles, and tactical combat systems.
Based on this multi-factor approach, six companies stand out as meeting most of our criteria (highlighted in green in the table above).
Unsurprisingly, all six companies have performed exceptionally well since Russia's invasion of Ukraine three years ago. Even the weakest performer in our selection managed to outperform the S&P 500 by a factor of three. However, the performance disparities within the group are notable and raise a critical question: Can this level of outperformance be sustained?
To assess whether these companies can maintain their momentum or if “laggards” might catch up, we look at forward valuations using 12-month price-to-earnings ratios.
While Saab and Leonardo predictably command higher valuations given their remarkable performance runs, what's truly surprising is that despite their extraordinary performance, their P/E ratios remain below 35x—relatively reasonable for companies experiencing such dramatic growth.
Nevertheless, considering the parabolic trajectories of Leonardo and Saab, a prudent alternative strategy would be to shift focus toward the "second wave" of European Defense Specialists. These companies—Thales SA (HO-FR), BAE Systems plc (BA-GB), Indra Sistemas SA (IDR-ES), and QinetiQ Group plc (QQ-GB)—stand to benefit substantially from the recently announced ReArm Europe program and have yet to experience a dramatic valuation expansion.
The global fertility rate has dropped from around 5 children per female in the 1960’s to a little above 2 now. It is expected to fall below replacement level (2.1) over the next quarter-century. The map below shows where fertility remains above the replacement level: Africa, the Stans (former Russian Republics like Kazakhstan and Uzbekistan plus Afghanistan and Pakistan) and a few countries in South America and elsewhere. It also highlights countries with abnormally low fertility rates like South Korea (under 0.6) and China (1).
The table below lists reasons why fertility rates have fallen so much; from urbanization, lifestyle, policy and biology (contraception improvements, pollution, biological age limits and declining sperm counts). It is difficult to imagine a rapid reversal of those factors.
You Cannot Fake Population Growth
One of the main implications of slower population growth is the impact on real economic growth. Take Scott Bessent’s new 3-3-3 target, which aims for a 3% deficit, 3 million barrel/day of extra US oil production, 3% real GDP growth). Real GDP growth relies on a combination of population growth and productivity growth. In order to achieve 3% real GDP growth, productivity will need to surge to offset the stagnation in the working age population. On the deficit side, an older population is a challenge to spending reductions.
The map below highlights how populations around the world are expected to evolve over the next five years. Most of Europe, Russia, China, Japan and South Korea are expected to have shrinking population whereas other developed economies are expecting limited growth.
Slowing population growth will also be accompanied by a much older population with higher healthcare spending. Considering that in the United States, healthcare expenditures already represent close to 20% of GDP , any productivity improvement in the sector will have to be considered for healthcare to stop growing as a percentage of the economy.
The chart below shows that the peak growth in the elderly population is happening now while overall population growth is slowing. Common discourse implies that we are getting older, but you never hear that we are right in the middle of the peak intensity on a global basis.
A growing elderly population should benefit healthcare companies. The table below highlights companies focused on improved healthcare productivity within our sustainable company investment universe; we expect a growing market for their products and services.
The chart below highlights each company’s stock performance since 2019. As we can see, there have been winners and losers compared to the S&P 500 without a clear trend for the group as a whole.
Senior Spend on Pills
An older population generally requires more health care which puts a strain on public finances and risks triggering intergenerational conflicts; the overwhelming older population will vote to maintain subsidized health services and the young will want better after-tax compensation. The map below illustrates the anticipated evolution of the population for people older than 72; there will be increases in the senior population everywhere in the world over the next five years, except for that little red dot on the map in Timor-Leste where life expectancy is just 69 years old .
The growing number of elderly (72+) will mean increase demand for medication. The table below shows pharmaceutical companies from our sustainable investment universe with solutions for a global population that is living longer.
Just like the performance chart for healthcare productivity companies, there have been winners and losers compared to the index. The two winners, Eli Lilly and Novo Nordisk, have mainly won because of their obesity pills that are not targeting elderly people, at all. As a result, there could be a catch up from the other companies based on growing demand for their products.
Senior Lodging is another segment that will have growing demand. The table below highlights sustainable companies providing senior lodging.
Real estate has suffered from higher interest rates since the pandemic. As we can see, performance for the group has been poor on an absolute and relative basis. Unlike other parts of real estate, like office that has oversupply, senior lodging should have better pricing power in the future.
Smaller Market for the Smallest
On the other hand, the large drop in fertility rate is leading to a totally different picture for children. As the map below shows, most countries will experience a large drop in child populations over the next five years. China and South Korea are among the places where the percentage decline is highest, while increases in the number of children will mainly occur in Africa. Considering the large increases in elderly and the large drop in future workers (children) over the next decade, the incentive to increase immigration, especially for skilled-care workers, should rise.
Companies that focus on products and services for children will face headwinds. The following table shows companies that will need to cope with a globally shrinking children market. Those companies are not negative from a sustainability basis, but we believe investors should be aware that demand for their products could fall.
The stock performance of these companies has been lacklustre other than Build-a-Bear which has boomed.
One of our high-conviction calls for the coming decade is the high likelihood of strong, sustained food inflation. To put it simply, absent a massive productivity surge, it is unlikely that farmers will be able to feed us the low-cost, high caloric diet we have become accustomed to, especially as climate change wreaks havoc with growing seasons and creates the conditions for ever more animal viral outbreaks.
Beyond this base case, a series of policy developments are unfolding in America that hold the potential to disrupt food supply chains. Immigration, tariffs, diminishing government oversight and particular cabinet picks are sparks that have been lit by Trump in 2025 and are on the cusp of unleashing a surge in food prices. Today’s note explores these sparks and what it means for publicly traded food companies.
Implications of Immigration
During his first days in office, Trump took action on immigration as promised during the campaign. The crackdown on inhabitants without legal status is expected to have significant consequences for American farmers. USDA data show that nearly half of the country’s crop farm workers are unauthorized to be in the United States (crop farm workers accounted for 75% of U.S. employment in agriculture in 2023).
Impacts from immigration will also be felt in the livestock sector, which makes up the balance of agricultural employment. Not surprisingly, meat-processor Tyson highlighted immigration policy as a source of uncertainty during the company’s latest earnings call.
The H-2A visa program for farmers to hire foreign agriculture workers temporarily could be seen as a workaround to the deportation issue. But the program’s future under Trump remains unclear; it was mentioned in Project 2025 leading some to anticipate a more challenging approval process. The popularity of these visas (see chart below) underscores the shortage of farm labor in the U.S.; certifications nearly tripled in the last decade. Still, this program is an expensive option - farmers must cover transport, shelter and meal costs for employees in addition to wages that are tied to state minimums.
Investment in automation could be one response to higher labor costs, benefitting companies like Deere, but we remain cautious. Depressed commodity prices, relatively higher interest rates and ongoing tariff uncertainties will make farmers hesitant to spend on equipment upgrades. Subsidies could provide relief (the farm bill has been up for renegotiation since 2023), but increased spending appears challenging under an administration so focused on budget cuts. Furthermore, farm equipment-makers face their own tariff risks: China has targeted farm equipment in its retaliation to U.S. tariffs and last fall Trump threatened a 200% tariff on Deere over the company’s Mexico-based production.
Troubles from Tariffs
On February 4th, Trump imposed a 10% blanket tariff on all products imported from China and is set to impose 25% on Canada and Mexico beginning March 1st. Meanwhile, he also is threatening further duties on European imports. Unless loopholes are created, the food sector will not come out unscathed.
About 15% of total food consumed in the U.S. is imported and the vast majority of this comes from China, Mexico and Canada. In the chart below, we show the impact on CPI food inflation. We assume 15% of the total food basket is slapped with a 25% tariff, while the rest remains at the 2024 annual rate of 2.2%. In this scenario, food price inflation will average close to 6% over the next year, simply due to the tariff effect. With the exception of the COVID period, one has to return to the 1990s to see this level of U.S. food inflation.
Note, this could be a conservative estimate of food inflation, since it does not account for the rising prices of many other input costs also subject to tariffs. For example, the 25% tariff applied to all aluminum imports will affect the cost of packaging (aluminum cans). And as noted in the section below, the cost of fertilizers is a major concern.
As the chart below shows, about one quarter of all fertilizers used in the U.S. are derived from potash. Canada supplies virtually all of the potash used as fertilizer in the U.S. Reliance on foreign sources of nitrogen is considerably less (between 6%–13% of total nitrogen consumption has been imported since 2020). Finally, phosphate imports represent between 6-16% of total phosphate, virtually all of it sourced from Peru and Morocco (countries that are not yet in the crosshairs of Trump).
The bottom line is that Trump’s 25% blanket tariffs will affect about one quarter of all fertilizer used in the U.S., which risks being another important source of inflation to the extent that this input cost is inevitably passed on to end food prices.
Loosey Goosey Regulation (Avian Flu)
Anyone reading American press will know that the price of eggs has become a sore point for many consumers. Avian flu (a.k.a. H5N1 virus) has caused the price of eggs to skyrocket, as 20 million egg-laying chickens have died from the virus in the past quarter.
Unfortunately, it is extremely unlikely that the U.S. H5N1 crisis will end soon. The outbreak is in part a government failure; there is a large consensus view that the USDA did not act swiftly and aggressively enough to stem the virus when it could and it is unlikely a coincidence that other North American jurisdictions have had far more success controlling outbreaks. It is an open question whether the new head of the USDA (Brooke Rollins) will implement policy to stem the animal losses.
Perhaps ironically, some of the biggest American egg producers have seen their profitability and stock price benefit from the outbreak. The two largest publicly traded egg producers are Cal-Maine Foods (CALM US) and Vital Farms (VITL US). Both have seen their stock price skyrocket in the past years, but for sustainability investors looking to get long, only one of these companies merits attention. CALM US has a terrible environmental track record and overall low rankings in CSRHub scores. Moreover, and probably not a coincidence, one reason why the company has been profitable over the past year is because they are a beneficiary of generous H5N1 indemnities: when outbreaks happen, the federal government pays to compensate farmers for the culling of birds and sanitizing of facilities; Cal-Maine has been one of the largest recipients of this aid.
Conversely, VITL has largely avoided avian flu outbreaks over the past three years and is routinely ranked highly for more sustainable practices. Investing in egg stocks at this juncture is a high-risk endeavor, but for investors that like the odds, VITL US is our favored play.
Cabinet Picks Stir the Pot
Although picked for Health and Human Services Secretary, nominee Robert F. Kennedy Jr. (RFK Jr.) will have important implications for food and ag. This role has limited authority over agriculture policy, but does oversee the Food and Drug Administration which regulates food safety. RFK Jr. has been vocal in his criticism of ultra-processed foods and pesticides use. As part of the Make America Healthy Again campaign, RFK Jr. has pledged to take on Big Food.
Weed and pest management has become a key component in agricultural production. Globally, the U.S. is second only to Brazil for total use of pesticides. The charts below show the pesticides use per hectare of farmland (kg/ha).
Over the last decade, pesticide use per unit of land has stabilized in Europe but continued to grow in the United States. This reflects stricter regulations in the EU, but also the dominance of pesticide-intensive crops such as corn and soybeans in America.
Given the environmental and public health risks associated with heavy pesticide use, stronger regulation is not a bad thing. With RFK Jr. selected by a Republican president known for strong-arming, pesticide regulation could gain more conservative support than in the past. However, this would present an enormous hurdle for the agri-science industry (see our note “Agriculture’s Addiction Problem”, September 1, 2022). Curtailing pesticide use would, all things equal, reduce crop yields (food supply) and (once again) put upward pressure on prices.
How to Invest
High food price environments often favor the major food processors like General Mills, Campbell’s, Hershey’s, etc, since they also have the ability to pass on higher input costs in (i.e. have pricing power). Indeed, these companies outperformed the broad market in 2022 when COVID induced supply chain delays caused a spike in food inflation and they also outperformed during the 1970s’ food inflation spikes.
However, as readers of our previous work will know, investing in these companies is no easy task for investors who prioritize sustainability (please see “No Free Lunch: Challenges and Opportunities for Engagement in the Food Supply Chain”, March 7, 2024). Controversies are common (greenwashing, anti-competitive practices) and the holding of subsidiaries that often focus on unhealthy snacks makes these companies often unappealing.
For sustainability investors looking to get long food manufacturing business to position for the likely wave in food price inflation, one approach is to hold a broad basket of the major food companies, and exclude the companies that contribute most to the sweets and snack foods category: Pepsi Co., Mondelez, Hershey, Nestle, Barry Callebaut and Kellanova (the latter is the snack division spun off from Kellogg’s).
Note that in our 2025 Investment Playbook, we highlighted Mondelez and Pepsi as two short candidates based on the premise that they do not fit RFK’s view of healthy food. These companies have already lost value in the run up to his confirmation.
With these exclusions in place, the below table highlights some of the food companies with good sustainability scores that have a lower contribution to the unhealthiest aisles in the grocery store. Of course, to be taken with a grain of salt, while these companies have less revenues from snacks and sweets, some of their products are still deemed unhealthy.
From a financials perspective, Kraft Heinz has higher margins, a lower valuation and positive EPS growth. General Mills also exhibits higher profitability and better growth. Unsurprisingly for consumer staples, all of the companies have forward P/E valuations below the SP500.